Related Experiment Videos
Cyclosporin for atopic dermatitis in children
J I Harper1, J Berth-Jones, R D Camp
1Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, London, UK.
Dermatology (Basel, Switzerland)
|September 11, 2001
Summary
Cyclosporin A is recommended for severe pediatric atopic dermatitis cases unresponsive to other treatments. Careful monitoring of blood pressure and kidney function is essential due to potential toxicity.
Area of Science:
- Dermatology
- Pediatrics
- Immunology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting children.
- Refractory AD cases often require systemic treatment options.
- Cyclosporin A (CsA) is a potent immunosuppressant with potential for treating severe AD.
Framework:
- Guidelines for CsA use in pediatric AD were established at a UK consensus conference in April 2000.
- The consensus focused on defining appropriate patient selection and monitoring protocols.
- Evidence-based recommendations were formulated by expert participants.
Implementation:
- Cyclosporin A is indicated only for the most severe, refractory cases of pediatric atopic dermatitis.
- Treatment initiation requires careful patient assessment and consideration of alternative therapies.
- Physician expertise in managing systemic immunosuppressants is crucial.
Implications:
- Appropriate use of CsA can offer a therapeutic option for children with debilitating AD.
- Vigilant monitoring of blood pressure and renal function is mandatory to mitigate risks.
- Long-term safety data and follow-up are essential for optimizing CsA therapy in pediatric populations.